Read more

November 21, 2024
1 min read
Save

Oral IL-23 inhibitor icotrokinra shows efficacy for plaque psoriasis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • 64.7% of patients treated with once-daily icotrokinra achieved IGA scores of 0 or 1 by week 16 vs. 8.3% treated with placebo.
  • 49.6% of icotrokinra-treated patients reached PASI 90 vs. 4.4% of placebo.
Perspective from Joel M. Gelfand, MD, MSCE

New, positive topline data found icotrokinra to be effective for the treatment of moderate to severe plaque psoriasis in patients aged 12 years and older, Protagonist Therapeutics and Johnson & Johnson announced.

Formerly known as PN-235, icotrokinra (JNJ-2113; Protagonist Therapeutics, Johnson & Johnson) is a first-in-class targeted oral peptide that inhibits the interleukin-23 receptor. The drug has been tested for its efficacy in multiple trials, the most recent being the phase 3 investigational studies ICONIC-LEAD and ICONIC-TOTAL.

Psoriasis 3
New, positive topline data found icotrokinra to be effective for the treatment of moderate to severe plaque psoriasis in patients aged 12 years and older. Image: Adobe Stock.

“These positive phase 3 results confirm the compelling efficacy and safety trends that were observed with the previous phase 2b FRONTIER-1 and -2 studies, highlighting icotrokinra’s potential as a best-in-class oral agent providing an ideal combination of significant skin clearance with demonstrated tolerability in a once-daily pill for treating plaque psoriasis,” Dinesh V. Patel, PhD, president and CEO of Protagonist, said in a press release.

In ICONIC-LEAD, 64.7% of patients treated with once-daily icotrokinra achieved IGA scores of 0 or 1 by week 16 vs. 8.3% treated with placebo. Similarly, nearly half (49.6%) of icotrokinra-treated patients reached PASI 90 vs. 4.4% of placebo by week 16.

By week 24, response rates increased with 74.1% and 64.9% of icotrokinra-treated patients reaching IGA 0 or 1 and PASI 90, respectively.

ICONIC-TOTAL also reportedly met the primary endpoint of IGA 0 or 1 at week 16 vs. placebo, according to the press release.

Safety findings were consistent with previous studies, including the phase 2 FRONTIER-1 and -2 trials. Treatment-emergent adverse events that occurred by week 16 were similar in both the icotrokinra and placebo groups (49.3% vs. 49.1%).

Reference: